Abbvie Inc.

Abbott Laboratories Corporation

Calico Life Sciences LLC

Abbvie Bahamas Limited

Michael J Dart

Jennifer M Frost

William A Carroll

Arturo Perez-Medrano

Teodozyj Kolasa

Sridhar Peddi

Xueqing Wang

Meena V Patel

Derek W Nelson

Tongmei Li

Bo Liu

Steven P Latshaw

Keith Brian Ryther

Karin Rosemarie Tietje

Jerome F Daanen

Lei Shi

Yunsong Tong

Philip R Kym

Arthur Gomtsyan

Michael E Kort

Alan S Florjancic

Marina Pliushchev

Michael D Meyer

Eric A Voight

Xiangdong Xu

Megan E Gallagher

Charles W Hutchins

Nan-Horng Lin

Lawrence A Black

Gregory A Gfesser

Robert G Schmidt

Mark W Holladay

Ramzi Farah Sweis

Qingwei I Zhang

Bruce Clapham

James T Wasicak

Phil B Cox

Seungwon Chung

Yat Sun Or

William H Bunnelle

Kevin R Woller

Erol K Bayburt

Tammie K Jinkerson

James P Sullivan

Hao Bai

Ryan G Keddy

Richard B Toupence

Paul P Ehrlich

John K Lynch

Stephen P Arneric

Kathleen J Murauski

Yun He

Clara I Villamil

John T Randolph

Michael R Schrimpf

Youssef L Bennani

Kevin B Sippy

Yi-Yin Ku

Sanjay R Chemburkar

Brian S Brown

Xenia Beebe Searle

Mark A Matulenko

Sou-Jen Chang

Dilinie P Fernando

Anurupa Shrestha

Yihong Li

Richard L Elliott

Mark A Lockwood

Lei Wang

Carmela Sidrauski

Jennifer M Pace

Jinhua Chen

Tedozyi Kolasa

Zhaoming Xiong

Daniela Barlocco Cristina

Kathleen Ann Martin

Marina A Pliushchev

Ramzi Farath Sweis

Marina Pliuschev

Keith B Ryther

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Modulators of the integrated stress pathway

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

Prodrug modulators of the integrated stress pathway

The present invention relates compounds of formula (I) wherein A and Rare as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

Compounds as cannabinoid receptor ligands

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and L, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as cannabinoid receptor ligands and uses thereof

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L, A, R, z, R, R, and Rare as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

The present application relates to thiazolylidene containing compounds of formula (I) wherein R, R, R, R, Land A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A, A, R, X, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present application relates to cannabinoid receptor ligands of formula (I) wherein X, A, R, R, R, R, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and Lare defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R, R, R, R, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Growing community of inventors

Highland Park, IL, United States of America

Michael J Dart